Atogepant (Qulipta) prior authorization at UPMC Health Plan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
UPMC Health Plan requires prior-authorization documentation for Atogepant (Qulipta): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
UPMC Health Plan reviews Atogepant (Qulipta) prior authorizations against its medical policy . UPMC Health Plan-specific context: Integrated payer-provider arm of UPMC (~4M members). Western PA dominant. The Highmark-UPMC consent decree (expired June 2019) governed cross-network access historically; subsequent commercial agreements maintain some access. PA Insurance Department oversight.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- UPMC Health Plan's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Highmark-vs-UPMC network access disputes (historical PA consent decree)
- Specialty drug PA
- Behavioral health prior auth
- Out-of-network reductions
Atogepant (Qulipta)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring CGRP injectable first
- Step therapy requiring 2+ oral preventives
- Episodic vs chronic indication restriction
- Quantity limit below daily dosing
Brand: Qulipta. Oral CGRP receptor antagonist (gepant). FDA-approved for episodic migraine prevention (2021) and chronic migraine prevention (April 2023).
Manufacturer patient-assistance program: AbbVie Complete — relevant when an UPMC Health Plan denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.upmchealthplan.com/providers) with the same packet plus an applicable, current clinical source supporting Atogepant (Qulipta)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal an UPMC Health Plan denial on DenialHelp.
Contact UPMC Health Plan
- Provider portal: https://www.upmchealthplan.com/providers
Frequently asked questions
What documentation does UPMC Health Plan need for Atogepant (Qulipta) prior auth?
UPMC Health Plan's typical PA packet for Atogepant (Qulipta): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at UPMC Health Plan?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for Atogepant (Qulipta) at UPMC Health Plan?
Preparation scenarios to check against the current notice and policy include: Highmark-vs-UPMC network access disputes (historical PA consent decree); Specialty drug PA; Behavioral health prior auth. These are not measured frequency claims. For Atogepant (Qulipta), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
How do I prep for a peer-to-peer with UPMC Health Plan on Atogepant (Qulipta)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Atogepant (Qulipta) PA packet
Open ApprovalHelp — generate a Atogepant (Qulipta) prior-auth packet tailored to UPMC Health Plan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com